National trends in prescription drug expenditures and projections for 2016

American Journal of Health-System Pharmacy

Volumn 73, Issue 14, 2016, Pages 1058-1075

  Schumock, Glen T ^a   Li, Edward C ^b   Suda, Katie J ^c,d   Wiest, Michelle D ^e   Stubbings, JoAnn ^a   Matusiak, Linda M ^f   Hunkler, Robert J ^f   Vermeulen, Lee C ^g,h  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f IQVIA   (United States)

^g University of Wisconsin Health   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BENDAMUSTINE; BEVACIZUMAB; BIOSIMILAR AGENT; BORTEZOMIB; CHICKENPOX VACCINE; DENOSUMAB; IMMUNOGLOBULIN; INFLIXIMAB; INFLUENZA VACCINE; LEDIPASVIR PLUS SOFOSBUVIR; NATALIZUMAB; NEW DRUG; NIVOLUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OCTREOTIDE; PACLITAXEL; PEGFILGRASTIM; PEMETREXED; PERTUZUMAB; PNEUMOCOCCUS VACCINE; PRESCRIPTION DRUG; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; SEVELAMER; TRASTUZUMAB; WART VIRUS VACCINE;

ARTICLE; DRUG APPROVAL; DRUG COST; DRUG USE; DRUG UTILIZATION; EXPIRATION DATE; HEALTH CARE SYSTEM; HEPATITIS C; HOSPITAL; HUMAN; LONG TERM CARE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREND STUDY; UNITED STATES; ECONOMICS; HEALTH CARE COST; HEALTH ECONOMICS; OUTPATIENT DEPARTMENT; TRENDS;

AMBULATORY CARE FACILITIES; DRUG APPROVAL; DRUG COSTS; ECONOMICS, HOSPITAL; HEALTH EXPENDITURES; HUMANS; PHARMACEUTICAL SERVICES; PHARMACIES; PRESCRIPTION DRUGS; UNITED STATES;

EID: 84977664970     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp160205     Document Type: Article

References (61)

1. Martin AB, Hartman M, Benson J, Catlin A. National health spending in 2014: faster growth driven by coverage expansion and prescription drug spending. Health Aff (Millwood). 2016; 35:150-60.
2. Keehan SP, Cuckler GA, Sisko AM et al. National health expenditure projections, 2014-24: spending growth faster than recent trends. Health Aff (Millwood). 2015; 34:1407-17.
3. Freundlich N. Keep the focus on rising drug prices, not smirking Shkreli (February 8, 2016). http://reforminghealth.org/2016/02/08/keep-the-focus-on-rising-drug-prices-not-smirking-shkreli/(accessed 2016 Mar 2).
4. Thomas Z, Swift T. Who is Martin Shkreli-'the most hated man in America'? (September 23, 2015). www.bbc.com/news/world-us-canada-34331761 (accessed 2016 Mar 3).
5. Winslow R. Cost of skin drugs rising rapidly, study shows (November 26, 2015). www.wsj.com/articles/prescription-skin-drugs-explode-in-costs-study-shows-1448467254 (accessed 2016 Mar 2).
6. Leopold C, Chambers JD, Wagner AK. Thirty years of media coverage on high drug prices in the United States-a never-ending story or a time for change? Value Health. 2016; 19:14-6.
7. Johnson C, Dennis B. How an $84, 000 drug got its price: 'let's hold our position . . . whatever the headlines.' (December 1, 2015). www.washingtonpost.com/news/wonk/wp/2015/12/01/how-an-84000-drug-got-its-price-lets-hold-our-position-whatever-the-headlines/(accessed 2016 Mar 2).
8. Tefferi A, Kantarjian H, Rajkumar SV et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015; 90:996-1000.
9. Rocco P, Gellad W, Donohue J. How much does Congress care about drug prices? Less than it should (January 13, 2016). http://healthaffairs.org/blog/2016/01/13/how-much-does-congress-care-about-drug-prices-less-than-it-should/(accessed 2016 Mar 2).
10. Schumock GT, Li EC, Suda KJ et al. National trends in prescription drug expenditures and projections for 2014. Am J Health-Syst Pharm. 2014; 71:482-99.
11. Schumock GT, Li EC, Suda KJ et al. National trends in prescription drug expenditures and projections for 2015. Am J Health-Syst Pharm. 2015; 72:717-36.
12. National Sales Perspectives [proprietary database]. Plymouth Meeting, PA: IMS Health; 2016.
13. IMS Health. Uniform System of Classification (March 2008). www.imshealth.com/files/web/IMSH%20Institute/USC-Classiification-Process-2011.pdf (accessed 2016 Mar 30).
14. Biogen. FDA accepts biologics license application for Zinbryta (daclizumab high-yield process) for treatment of MS (April 29, 2015). http://media.biogen.com/press-release/corporate/fda-accepts-biologics-license-application-zinbryta-daclizumab-high-yield-pro (accessed 2016 Feb 22).
15. Gilead Sciences. Gilead submits new drug application to U.S. Food and Drug Administration for single tablet regimen for HIV containing rilpivirine, emtricitabine and tenofovir alafenamide (R/F/TAF) (July 1, 2015). www.gilead.com/news/press-releases/2015/7/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-single-tablet-regimen-for-hiv-containing-rilpivirine-emtricitabine-and-tenofovir-alafenamide-rftaf (accessed 2016 Feb 22).
16. Gilead Sciences. Gilead submits new drug application to U.S. Food and Drug Administration for fixed-dose combination of emtricitabine/tenofovir alafenamide for HIV treatment (April 7, 2015). www.gilead.com/news/press-releases/2015/4/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-fixeddose-combination-of-emtricitabinetenofovir-alafenamide-for-hiv-treatment (accessed 2016 Feb 22).
17. PR Newswire. FDA accepts Bayer's biologics license application for investigational treatment option in hemophilia A (March 4, 2015). www.prnewswire.com/news-releases/fda-accepts-bayers-biologics-license-application-for-investigational-treatment-option-in-hemophilia-a-300045306.html (accessed 2016 Feb 22).
18. PR Newswire. Jazz Pharmaceuticals announces U.S. FDA acceptance for filing with priority review of NDA for defibrotide for hepatic veno-occlusive disease (September 30, 2105). www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-us-fda-acceptance-for-filing-with-priority-review-of-nda-for-defibrotide-for-hepatic-veno-occlusive-disease-300151412.html (accessed 2016 Feb 22).
19. Business Wire. Xadago (safinamide) new drug application (NDA) accepted for filing by the U.S. Food and Drug Administration (FDA) (March 2, 2015). www.businesswire.com/news/home/20150302006405/en/Xadago%C2%AE-safinamide-Drug-Application-NDA-Accepted-Filing (accessed 2016 Feb 22).
20. Gilead Sciences. Gilead announces U.S. FDA priority review designation for sofosbuvir/velpatasvir for treatment of all genotypes of chronic hepatitis C infection (January 4, 2016). www.gilead.com/news/press-releases/2016/1/gilead-announces-us-fda-priority-review-designation-for-sofosbuvirvelpatasvir-for-treatment-of-all-genotypes-of-chronic-hepatitis-c-infection (accessed 2016 Feb 2).
21. Teva Pharmaceutical Industries Ltd. Teva announces FDA acceptance of the biologics license application for reslizumab (June 15, 2015). www.tevapharm.com/news/teva-announces-fda-acceptance-of-the-biologics-license-application-for-reslizumab-06-15.aspx (accessed 2016 Feb 22).
22. Intercept. FDA extends PDUFA date for obeticholic acid for the treatment of PBC (December 17, 2015). https://globenewswire.com/news-release/2015/12/17/796641/0/en/FDA-Extends-PDUFA-Date-for-Obeticholic-Acid-for-the-Treatment-of-PBC.html (accessed 2016 Feb 22).
23. Sanofi. Sanofi new drug application for lixisenatide accepted for review by FDA (September 29, 2015). www.news.sanofi.us/2015-09-29-Sanofi-New-Drug-Application-for-Lixisenatide-Accepted-for-Review-by-FDA (accessed 2016 Feb 22).
24. Business Wire. Acadia Pharmaceuticals announces FDA priority review of Nuplazid (pimavanserin) new drug application for Parkinson's disease psychosis (November 2, 2015). www.businesswire.com/news/home/20151102005516/en/ACADIA-Pharmaceuticals-Announces-FDA-Priority-Review-NUPLAZID%E2%84%A2 (accessed 2016 Feb 22).
25. Business Wire. Teva announces FDA acceptance of NDA for SD-809 for treatment in Huntington disease (August 12, 2015). www.businesswire.com/news/home/20150812005421/en/Teva-Announces-FDA-Acceptance-NDA-SD-809-Treatment (accessed 2016 Feb 22).
26. Roche. FDA grants priority review for venetoclax new drug application (January 12, 2016). www.roche.com/investors/updates/inv-update-2016-01-12.htm (accessed 2016 Feb 22).
27. PR Newswire. FDA accepts Amgen's new drug application for novel intravenous calcimimetic Etelcal-cetide (November 6, 2015). www.prnewswire.com/news-releases/fda-accepts-amgens-new-drug-application-for-novel-intravenous-calcimimetic-etelcalcetide-300174208.html (accessed 2016 Feb 22).
28. PR Newswire. Valeant announces FDA acceptance of BLA submission for brodalumab in moderate-to-severe plaque psoriasis (January 25, 2015). www.prnewswire.com/news-releases/valeant-announces-fda-acceptance-of-bla-submission-for-brodalumab-in-moderate-to-severe-plaque-psoriasis-300208845.html (accessed 2016 Feb 22).
29. PR Newswire. Regeneron and Sanofi announce sarilumab biologics license application accepted for review by US FDA (January 8, 2016). www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-sarilumab-biologics-license-application-accepted-for-review-by-us-fda-300201389.html (accessed 2016 Feb 22).
30. Taylor P. Roche prepares to file atezolizumab for bladder cancer ( January 8, 2016). www.pmlive.com/pharma-news/roche-prepares-to-file-atezolizumab-for-bladder-cancer-901572 (accessed 2016 Feb 22).
31. Eli Lilly and Company. Lilly and Incyte announce submission of new drug application to FDA for oral once-daily baricitinib for treatment of moderate-to-severe rheumatoid arthritis (January 19, 2016). https://investor.lilly.com/releasedetail.cfm?ReleaseID=950678 (accessed 2016 Feb 22).
32. Food and Drug Administration. FDA news release: FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4 (January 28, 2016). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483828.htm (accessed 2016 Mar 30).
33. Food and Drug Administration. FDA news release: FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B (March 4, 2016). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm489266.htm (accessed 2016 Mar 30).
34. Taylor S. Digest: generic and biosimilar pipeline September 2015 to December 2018 (2015). https://www.futurescripts.com/FutureScripts/pdfs/for-members/Q3-2015-Generic-Pipeline-Report.pdf (accessed 2016 Mar 30).
35. Express Scripts. Issues document: patent expirations (2013-2017) (May 6, 2013). www.centerlighthealthcare.org/images/uploads/Brand-Name-Drugs-with-Patent-Expirations-2013-2017.pdf (accessed 2016 Mar 30).
36. Stone K. Which popular drugs are going off patent in 2013-2016? (December 16, 2014). http://pharma.about.com/od/BigPharma/a/Which-Popular-Drugs-Are-Going-Off-Patent-In-2013-2016.htm (accessed 2016 Feb 29).
37. EP Vantage. Breakthrough designation quickens FDA approval pace in 2014 (January 5, 2015). http://epvantage.com/Universal/View.aspx?type=Story&id=550480&isEPVantage=yes (accessed 2016 Feb 22).
38. Eli Lilly and Company. Lilly receives FDA breakthrough therapy designation for abemaciclib-a CDK 4 and 6 inhibitor-in advanced breast cancer (October 8, 2015). www.prnewswire.com/news-releases/lilly-receives-fda-breakthrough-therapy-designation-for-abemaciclib-a-cdk-4-and-6-inhibitor-in-advanced-breast-cancer-300156371.html (accessed 2016 Feb 22).
39. AstraZeneca. Durvalumab granted breakthrough therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer (February 17, 2016). www.astrazeneca.com/media-centre/press-releases/2016/Durvalumab-granted-Breakthrough-Therapy-designation-by-US-FDA-for-treatment-of-patients-with-PD-L1-positive-urothelial-bladder-cancer-17022016.html (accessed 2016 Feb 22).
40. Redbook Online [online database]. Greenwood Village, CO: Truven Health Analytics (accessed 2016 Feb 22).
41. Food and Drug Administration. Unapproved drugs initiative (December 15, 2014). www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm118990.htm (accessed 2016 Mar 2).
42. Aitken M, Kleinrock M. Global medicines use in 2020: outlook and implications. Parsippany, NJ: IMS Institute for Healthcare Informatics; 2015 Nov.
43. Conti RM, Rosenthal MB. Pharmaceutical policy reform-balancing affordability with incentives for innovation. N Engl J Med. 2016; 374:703-6.
44. Sisko AM, Keehan SP, Cuckler GA et al. National health expenditure projections, 2013-23: faster growth expected with expanded coverage and improving economy. Health Aff (Millwood). 2014; 33:1841-50.
45. The Express Scripts Labs. Express Scripts 2015 drug trend report (March 2016). http://lab.express-scripts.com/lab/drug-trend-report (accessed 2016 Apr 4).
46. Food and Drug Administration. Novel new drugs: 2014 summary (January 2015). www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM430299.pdf (accessed 2016 Mar 30).
47. Denniston MM, Jiles RB, Drobeniuc J et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014; 160:293-300.
48. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C (2016). www.hcvguidelines.org (accessed 2016 Mar 30).
49. Centers for Medicare and Medicaid Services. Medicaid drug rebate program notice: Assuring Medicaid beneficiaries' access to hepatitis C (HCV) drugs (November 5, 2015). www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/Rx-Releases/State-Releases/state-rel-172.pdf (accessed 2016 Mar 30).
50. Rodriguez-Gutierrez R, Shah ND, Montori VM. Predicting the overuse of PCSK-9 inhibitors. JAMA. 2015; 314:1909-10.
51. EMD Serono. EMD Serono specialty digest, 11th edition. www.specialtydigest.emdserono.com/Digest.aspx (accessed 2016 Feb 1).
52. Colgan K, Stubbings J, Choudry R, Knoer S. Developing a specialty pharmacy strategy: building a successful business model. Abstract presented at ASHP Midyear Clinical Meeting. New Orleans, LA; 2015 Dec.
53. Ignjatovic T. Biosimilars still to make an impact in the UK (July 10, 2013). www.datamonitorhealthcare.com/biosimilars-still-to-make-an-impact-in-the-uk/(accessed 2016 Mar 2).
54. Pollack A. Drug goes from $13.50 a tablet to $750 overnight (September 20, 2015). www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html?-r=0 (accessed 2016 Mar 30).
55. American Society of Health-System Pharmacists. ASHP statement for the record: "developments in the prescription drug market" (February 4, 2016). www.ashp.org/menu/Advocacy/FederalIssues/OtherIssues/ASHP-Statement-for-the-Record-Developments-in-the-Prescription-Drug-Market.html (accessed 2016 Mar 2).
56. Wiske CP, Ogbechie OA, Schulman KA. Options to promote competitive generics markets in the United States. JAMA. 2015; 314:2129-30.
57. Health Resources and Services Administration. 340B Drug Pricing Program omnibus guidance (August 28, 2015). www.federalregister.gov/articles/2015/08/28/2015-21246/340b-drug-pricing-program-omnibus-guidance (accessed 2016 Mar 30).
58. Hartke PL, Vermeulen LC, Hoffman JM et al. Accuracy of annual prescription drug expenditure forecasts in AJHP. Am J Health-Syst Pharm. 2015; 72:1642-8.
59. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures-2005. Am J Health- Syst Pharm. 2005; 62:149-67.
60. American Society of Health-System Pharmacists. ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health-Syst Pharm. 2008; 65:1368-84.
61. Amgen. FDA approves Imlygic (talimogene laherparepvec) as first oncolytic viral therapy in the US (October 27, 2015). www.amgen.com/media/news-releases/2015/10/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us/(accessed 2016 Feb 22).